Association of point-of-care testing for sST2 with clinical outcomes in patients hospitalized with heart failure.

ABSTRACT:

Aims

This study aimed to investigate the association of soluble suppression of tumorigenicity-2 (sST2) measured by point-of-care testing assay with clinical outcomes in patients hospitalized with heart failure after adjusting for other predictors including N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT).

Methods

A total of 1726 consecutive patients hospitalized with heart failure from July 2015 to December 2021 were enrolled. Baseline serum sST2 concentrations were measured by immunofluorescence assay. Primary endpoint event was the composite of all-cause death, heart transplantation, or left ventricular assist device.

Results

During the median follow-up duration of 682 days, 434 patients (25.1%) suffered from pr

SUBMITTER: Chen Y 

PROVIDER: S-EPMC11424329 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature